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Abstract 
Platinum-based regimens are recommended as first-line chemotherapy for advanced non-small 
cell lung cancer (NSCLC), and docetaxel is usually used as second-line chemotherapy. So far, 
analyses of efficacy outcomes have not yet been systematically performed using large patient 
cohorts in each of the platinum- and docetaxel-based chemotherapies. The present meta-analysis 
aims to investigate the prognostic factors affecting overall survival (OS), progression-free 
survival (PFS) or time to progression (TTP), and overall response rate (ORR) in carboplatin- 
and paclitaxel-based first-line chemotherapy and docetaxel-based second-line chemotherapy for 
advanced NSCLC. 
A literature search in PubMed for randomized phase II and III clinical trials in patients with 
NSCLC treated with carboplatin and paclitaxel as first-line chemotherapy and with docetaxel as 
second-line chemotherapy was performed, and prognostic factors affecting OS, PFS or TTP, 
and ORR were investigated by regression analysis. 
Sixty-one treatment arms in 53 phase II and III clinical trials of carboplatin- and 
paclitaxel-based treatment and 39 treatment arms in 31 phase II and III clinical trials of 
docetaxel-based treatment were included in the analyses. 
The region of Asia was found to be a prognostic factor contributing to longer OS following 
treatment with carboplatin and paclitaxel as first-line chemotherapy and docetaxel as 
second-line chemotherapy. Furthermore, low percentage of performance status (PS) 2 was 
found to be a prognostic factor of longer OS in patients treated with docetaxel as second-line 
chemotherapy. 
More global clinical trials in patients with NSCLC are expected to be performed across various 
regions and considering our findings, regional differences between Asian and non-Asian 
population, including Caucasians, should be considered in the design and interpretation of the 
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results of global clinical trials of novel agents in patients with advanced NSCLC. Furthermore, 
the ratio of patients with PS 2 should be considered in the design of global clinical trials of 
novel agents used in combination with docetaxel as second-line chemotherapy. 
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1. Introduction 
Lung cancer is the leading cause of death related to cancer worldwide, accounting for 12.9% of 
the 1.8 million total cases of cancer and 19.4% of the 1.59 million deaths in 2012 [1]. Non-small 
cell lung cancer (NSCLC) accounts for 85% of all cases of lung cancer and approximately 70% 
of patients with NSCLC present with locally advanced or metastatic disease at the time of 
diagnosis [2]. The five-year survival rate of NSCLC patients with Stage III and IV disease is 9% 
and 13%, respectively [3]. 
First-line chemotherapy for squamous cell carcinoma, adenocarcinoma with mutated epidermal 
growth factor receptor (EGFR), and anaplastic lymphoma kinase (ALK)-negative type advanced 
NSCLC are platinum doublet-based chemotherapies, including cisplatin or carboplatin. 
Cisplatin or carboplatin is used in combination with paclitaxel, docetaxel, gemcitabine, 
etoposide, vinblastine, vinorelbine, pemetrexed, or albumin-bound paclitaxel. A tyrosine kinase 
inhibitor (TKI), either erlotinib, afatinib, or gefitinib, is recommended to be added in 
EGFR-mutation positive patients with NSCLC, and crizotinib is recommended for 
ALK-positive patients with NSCLC as first-line therapy. Second-line chemotherapy includes 
docetaxel for patients with NSCLC following treatment with platinum doublet-based 
chemotherapies [4]. Therefore, to date, both platinum doublet-based chemotherapies as first-line 
treatment and docetaxel-based chemotherapy as second-line treatment are still the cornerstone 
of NSCLC treatment. 
In recent decades, numerous molecular-targeted drugs have been developed to improve overall 
survival (OS) through global clinical trials in combination with platinum doublet-based 
chemotherapies as first-line treatment, such as carboplatin/paclitaxel, cisplatin/gemcitabine, and 
cisplatin/pemetrexed, and with docetaxel as second-line treatment. Among them, bevacizumab, 
a vascular endothelial growth factor receptor (VEGFR) inhibitor, demonstrated OS prolongation 
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in clinical trials in combination with carboplatin and paclitaxel as first-line chemotherapy in 
patients with NSCLC [5]. Moreover, ramucirumab, a VEGFR inhibitor, demonstrated OS 
prolongation in clinical trials in combination with docetaxel as second-line chemotherapy in 
patients with NSCLC [6]. 
Outcomes of global clinical trials represent data from patients with different background, 
including quite a few regions and countries. The differences in patient background may 
influence treatment efficacy in terms of overall response rate (ORR), progression-free survival 
(PFS)/time to progression (TTP), and OS in global clinical trials that are usually conducted by 
applying add-on regimens to standard chemotherapies. These differences may complicate the 
interpretation of the results. Therefore, it is very important to comprehend prognostic factors 
influencing the efficacy of standard chemotherapies in advance. Such understanding will bring 
clinical trials on advanced NSCLC to successful results and provide appropriate consideration 
and evaluation of the results of clinical trials on advanced NSCLC. 
Using a meta-analysis, Soo et al. reported that median OS and ORR in Asian and Caucasian 
trials of platinum doublet-based chemotherapies as first-line therapy significantly differed [7]. 
Using a meta-analysis of the individual data from nine randomized trials of second-line 
chemotherapy, Di Maio et al. reported that gender, performance status (PS), tumor histology, 
disease stage, type of previous treatment, and response to first-line therapy were factors 
significantly associated with OS [8]. However, analyses of efficacy outcomes have not yet been 
systematically performed using large patient cohorts for each of the platinum doublet-based 
chemotherapies as first-line treatment and docetaxel as second-line treatment widely used in 
global clinical trials. 
In this meta-analysis, I first investigated factors associated with OS, PFS/TTP, and ORR in 
patients with advanced-stage NSCLC treated with carboplatin and paclitaxel as first-line 
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chemotherapy and docetaxel as second-line chemotherapy. Second, the association between 
prognostic factors affecting ORR, PFS, and OS was assessed in terms of continuity of clinical 
endpoints for carboplatin- and paclitaxel-based chemotherapy and for docetaxel-based 
chemotherapy, respectively. Third, I assessed the association of prognostic factors of first- and 
second-line treatments in terms of continuity of medical treatment. I believe that the findings in 
this study provide an important insight that is critical to informing future global clinical trials on 
NSCLC using combinations of carboplatin and paclitaxel as first-line treatment and docetaxel as 
second-line treatment and foster the interpretation of efficacy results not only for the 
pharmaceutical industry but also for clinical researchers. 
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2. Materials and methods 
2.1. Carboplatin and paclitaxel as first-line therapy 
2.1.1. Trial selection and database construction 
Articles of randomized clinical trials with chemotherapy regimens of carboplatin and paclitaxel 
as first-line therapy in patients with advanced NSCLC published between January 1, 2000 and 
December 31, 2013 were identified through a systematic search in PubMed. The following 
keywords were used, and results were limited to articles published in English: "non-small-cell 
lung," "carboplatin," "paclitaxel," "Phase II," "Phase III" and "randomized controlled trial".  
Trials included were randomized phase II or III clinical trials in advanced NSCLC patients 
treated with carboplatin and paclitaxel as first-line chemotherapy with the information on both 
OS and ORR. Trials were excluded for the following reasons by manual review: post-operative 
or pre-operative chemotherapy, other than first line therapy, chemoradiation therapy, other than 
paclitaxel plus carboplatin therapy, patient selection by biomarker, review/duplicate 
publication/sub analysis/ combined analysis, trials without information on efficacy data (both 
OS and ORR) or sufficient baseline patient characteristics, trials with the number of patients 
less than 40 and other than randomized trials. To avoid bias, two observers independently 
extracted data from the articles. 
2.1.2. Data extraction 
Extracted data included publication year, patient characteristics (age, gender, Performance 
Status (PS)), disease stage, histological type of NSCLC, treatment information (paclitaxel 
administration schedule), trial characteristics (phase, year of trial initiation, region (Asian or 
non-Asian trials), and number of patients), and efficacy information (median OS, PFS or TTP, 
and ORR). Asian trials were defined as those conducted in Japan, China or Taiwan. One Asian 
multinational trial which was conducted in Hong Kong, China, Indonesia, Japan, Malaysia, the 
Philippines, Singapore, Taiwan, and Thailand was included in this category since the majority 
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of patients were Japanese and Chinese. Non-Asian trials were defined as those conducted in US 
or European countries and some others. Multinational trials conducted in both Asian and 
non-Asian regions were classified as “others.” Percentages of males, PS 2 or Karnofsky 
performance status of 50-60, stage IV disease, and adenocarcinoma were used as variables for 
gender, PS, disease stage, and histological type of NSCLC, respectively. OS and ORR were 
extracted for all the treatment arms using published data. Data on smoking status, weight loss 
and EGFR mutation were not included due to limited data availability in each of the articles. 
2.1.3. Data analysis 
The following analyses were performed on many heterogeneous studies with different kinds of 
patient characteristics to investigate potential factors that influence efficacy variables of median 
OS TTP/PFS and ORR.  
Simple linear regression analyses were performed to investigate factors that influence efficacy 
variables of median OS and TTP/PFS using the following variables: number of patients, trial 
phase, year of trial initiation, region, paclitaxel administration schedule, median age, percentage 
of male patients, percentage of PS2 patients, percentage of patients with stage IV disease and 
percentage of patients with adenocarcinoma, taking the number of patients in each study into 
consideration. A p<0.1 was considered to identify potential factors for multiple linear regression 
analyses. Subsequently, using identified factors, multiple linear regression analyses with 
variable selection method (stepwise approach using p < 0.05) were performed to identify factors 
affecting OS and TTP/PFS. 
In a similar manner, univariate logistic regression analyses were conducted for ORR using the 
same variables. A p<0.1 was considered to identify potential factors for multivariate logistic 
regression analyses. Subsequently, using identified factors, multivariate logistic regression 
analyses with variable selection method (stepwise approach using p < 0.05) were performed to 
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identify factors affecting ORR. 
Mann-Whitney U test was used for comparisons of median OS, PFS/TTP and ORR between 
trials in Asian and non-Asian regions. 
A p < 0.05 was considered statistically significant throughout the analyses except where 
otherwise noted. Analyses were performed using SAS (version 9.2; SAS Institute Inc., Cary, 
NC, USA) and StatsDirect (version 2.7.9; StatsDirect Ltd, Altrincham, Cheshire, UK). 
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2.2. Docetaxel as second-line therapy 
2.2.1. Trial selection and database construction 
Articles of randomized clinical trials with chemotherapy regimen of docetaxel as second-line 
therapy in patients with advanced NSCLC published between January 1, 2000 and December 31, 
2014 were identified through a systematic search in PubMed. The following keywords were 
used, and results were limited to articles published in English: "non-small-cell lung," 
"docetaxel," "second line," "Phase II," "Phase III" and "randomized controlled trial". Trials 
included were randomized phase II or III clinical trials in advanced NSCLC patients treated 
with docetaxel as second line chemotherapy with the information on both OS and ORR. Trials 
in second or more line treatment of docetaxel were included. Trials were excluded for the 
following reasons by manual review: Other than second line therapy, other than docetaxel 
therapy, review/sub analysis, trials without information on efficacy data (both OS and ORR) or 
sufficient baseline patient characteristics, trials with the number of patients less than 25 and 
other than randomized trials. To avoid bias, two observers independently extracted data from 
the articles. 
2.2.2. Data extraction 
Extracted data included publication year, patient characteristics (age, gender, PS), disease stage, 
histological type of NSCLC, treatment information (docetaxel administration schedule and 
treatment line), trial characteristics (phase, year of trial initiation, region (Asian or non-Asian 
trials), and number of patients), and efficacy information (median OS, PFS or TTP, and ORR). 
Asian trials were defined as those conducted in Japan, China, Korea or Taiwan. Non-Asian 
trials were defined as those conducted in US or European countries and some others. 
Multinational trials conducted in both Asian and non-Asian regions were classified as “others.” 
Percentages of males, PS 2 or Karnofsky performance status of 50-60, stage IV disease, and 
adenocarcinoma were used as variables for gender, PS, disease stage, and histological type of 
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NSCLC, respectively. OS and ORR were extracted for all the treatment arms using published 
data. Data on smoking status, weight loss, first line or prior treatment and EGFR mutation were 
not included due to limited data availability in each of the articles. 
2.2.3. Data analysis 
The following analyses were performed on many heterogeneous studies with different kinds of 
patient characteristics to investigate potential factors that influence efficacy variables of median 
OS TTP/PFS and ORR.  
Simple linear regression analyses were performed to investigate factors that influence efficacy 
variables of median OS and TTP/PFS using the following variables: number of patients, trial 
phase, year of trial initiation, region, docetaxel administration schedule, treatment line of 
decetaxel, median age, percentage of male patients, percentage of PS2 patients, percentage of 
patients with stage IV disease and percentage of patients with adenocarcinoma, taking the 
number of patients in each study into consideration. A p<0.1 was considered to identify 
potential factors for multiple linear regression analyses. Subsequently, using identified factors, 
multiple linear regression analyses with variable selection method (stepwise approach using p < 
0.05) were performed to identify factors affecting OS and TTP/PFS. 
In a similar manner, univariate logistic regression analyses were conducted for ORR using the 
same variables. A p<0.1 was considered to identify potential factors for multivariate logistic 
regression analyses. Subsequently, using identified factors, multivariate logistic regression 
analyses with variable selection method (stepwise approach using p < 0.05) were performed to 
identify factors affecting ORR. 
Mann-Whitney U test was used for comparisons of median OS, PFS/TTP and ORR between 
trials in Asian or non-Asian regions and in patients with PS 2 of ≥15 or <15 %. 
A p < 0.05 was considered statistically significant throughout the analyses except where 
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otherwise noted. Analyses were performed using SAS (version 9.2; SAS Institute Inc., Cary, 
NC, USA) and StatsDirect (version 2.7.9; StatsDirect Ltd, Altrincham, Cheshire, UK). 
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3. Results 
3.1. Carboplatin and paclitaxel as first-line therapy 
3.1.1. Trial Characteristics 
The flowchart for trial selection is shown (Figure 1). A total of 333 articles were retrieved. As a 
result of manual literature review, 53 trials were ultimately selected to establish the database for 
the meta-analysis [9-61]. 
 
Figure 1 Flowchart of selecting trials for the analysis 
ORR: overall response rate, OS : overall survival 
 
Main characteristics of the 53 trials are listed (Table 1). A total of 61 treatment arms and 12,738 
patients with advanced NSCLC were included. The median number of patients per trial was 159 
(range 40–650) with most trials having a high proportion of males (67.0 %: range 20.9-100%). 
The median age was 63 years (range 54.0-77.4). There were 25 arms from phase II and 36 arms 
from phase III trials. Trials were classified into two groups by year of trial start, considering the 
timing of first approval of an EGFR TKI molecular-targeted agent: between 1995 and 2002 (36 
arms) and between 2003 and 2008 (21 arms). The median OS was 9.5 months (range 5.9-23.4) 
Trials identified by PubMed search
(N=333)
Selected trials for meta analysis
(N=53 trials)
Selected trials (N=89)
Trials excluded:
Post-operative or pre-operative chemotherapy(N=18)
Other than first line therapy(N=4)
Chemoradiation therapy(N=79)
Other than paclitaxel plus carboplatin therapy(N=77)
Patient selection by biomarker(N=3)
Review/duplicate publication/sub analysis/combined analysis(N=57)
Trials without information on efficacy data (both OS and ORR) or 
sufficient baseline patient characteristics(N=6)
Trials excluded:
Trials with the number of patients less than 40(N=22)
Other than randomized trials(N=14)
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for all arms, and median PFS/TTP was 5.1 months (range 2.9–7.2) for 54 arms. The median 
overall response rate was 27.1% for all arms (range 12.0-60.9). 
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Table 1 Characteristics of 61 treatment arms in the selected trials for the analysis  
Variables Overall 
Total number of trials 53 
Total number of arms 61 
Total number of patients 12,738 
Number of randomized patients per arm  
<160 31 
≥160 30 
Median (range) 159 (40-650) 
Phase a  
II 25 (41.0%) 
III 36 (59.0%) 
Year of trial initiation a  
1995-2002 36 (59.0%) 
2003-2008 21 (34.4%) 
unknown 4 (6.6%) 
Trial Region a  
Asia 11 (18.0%) 
Non-Asia 45 (73.8%) 
Others 5 (8.2%) 
Administration schedule of Paclitaxel a  
Weekly 9 (14.8%) 
Every 3 weeks 52 (85.2%) 
Median Age(range) 63 (54.0-77.4) 
Percentage of male patients (range) 67 (20.9-100) 
Percentage of PS2 patients (range) 3.3 (0-100) 
Percentage of patients with Stage IV disease(range) 79.5 (39.7-98.0) 
Percentage of patients with Adenocarcinoma (range) 52 (26.2-97.2) 
ORR (%)(range)  27.1 (12.0-60.9) 
PFS/TTP (months) (range)  5.1 (2.9-7.2) 
OS (months) (range) 9.5 (5.9-23.4) 
ORR: overall response rate, PFS: progression free survival, TTP: time to progression, OS: 
overall survival, PS: performance status 
a Percentage per arm 
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3.1.2. Regression analysis 
I selected year of trial initiation (1995–2002, 2003–2008), trial phase (II, III), trial region (Asia, 
non -Asia), number of patients (<160, ≥160), paclitaxel administration schedule (weekly, every 
3 weeks), median age (<63, ≥63), percentage of male patients (<70, ≥70), percentage of PS2 
patients (<10, ≥10), percentage of patients with stage IV disease (<80, ≥80), and percentage of 
patients with adenocarcinoma (<55, ≥55) as potential influencing factors. 
Identification of factors influencing OS 
In simple and linear regression analyses to identify factors influencing OS, year of trial 
initiation, trial region, median age and percentage of patients with adenocarcinoma were 
identified as factors potentially contributing to OS prolongation. Upon further multiple linear 
regression analyses, trial region (Asia) was identified as favorable factors significantly 
contributing to longer OS (Table 2). 
Identification of factors influencing PFS/TTP 
Year of trial initiation, percentage of male patients, percentage of patients with stage IV disease 
and percentage of patients with adenocarcinoma were identified as factors potentially 
contributing to PFS or TTP prolongation in simple and linear regression analyses. Further 
multiple linear regression analyses did not yield significant factors (Table 3). 
Identification of factors influencing ORR 
In univariate logistic regression analyses, trial region, paclitaxel administration schedule , 
percentage of male patients, percentage of PS2 patients, percentage of patients with stage IV 
disease and percentage of patients with adenocarcinoma were identified as factors potentially 
influencing ORR. Upon further multivariate logistic regression analyses, trial region (Asia), 
weekly administration schedule of paclitaxel, and patients with adenocarcinoma less than 55% 
of enrolled patients were identified as favorable factors significantly influencing ORR (Table 4). 
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Table 2 Factors influencing OS identified by linear regression analysis(Carboplatin and paclitaxel as first line therapy) 
Characteristics Category N 
Simple linear regression Multiple linear regression 
Regression coefficient SE P value Regression coefficient SE P value 
Year of trial initiation 
2003-2008 
1995-2002 
21 
36 
2.611  0.587  <0.0001 Excluded - - 
Phase  
III 
II 
36 
25 
0.221  0.912  0.8095 - - - 
Trial Region 
Non –Asia 
Asia 
45 
11 
-5.922  0.589  < 0.0001 -5.895 0.684 < 0.0001 
No. of randomized patients 
≥160 
<160 
30 
31 
0.538  0.787  0.4969 - - - 
Administration schedule of Paclitaxel 
Every 3 weeks 
Weekly 
52 
9 
1.169  0.979  0.2372 - - - 
Median Age 
≥63 
<63 
27 
26 
-1.237  0.694  0.0808 Excluded - - 
% of male patients 
≥70 
<70 
26 
35 
-0.840  0.650  0.2012 - - - 
% of PS2 patients 
≥10 
<10 
23 
36 
0.241  0.704  0.7334 - - - 
% of patients with Stage IV disease 
≥80 
<80 
30 
30 
-0.662  0.638  0.3037 - - - 
% of patients with Adenocarcinoma  
≥55 
<55 
25 
26 
1.733  0.658  0.0113 Excluded - - 
OS : overall survival, PS: performance status, SE: standard error, N: number of treatment arms,  
- : not used in the multiple regression analysis because p > 0.1, Excluded: excluded as a result of the step wise approach using p < 0.05 
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Table 3 Factors influencing PFS/TTP identified by linear regression analysis(Carboplatin and paclitaxel as first line therapy) 
Characteristics Category N 
Simple linear regression Multiple linear regression  
Regression coefficient SE P value Regression coefficient SE P value 
Year of trial initiation 
2003-2008 
1995-2002 
21 
31 
0.584 0.227  0.0132  Excluded - - 
Phase  
III 
II 
33 
21 
-0.162 0.389  0.6797  - - - 
Trial Region 
Non –Asia 
Asia 
38 
11 
-0.414 0.398  0.3034  - - - 
No. of randomized patients 
≥160 
<160 
29 
25 
-0.052 0.343  0.8800  - - - 
Administration schedule of Paclitaxel 
Every 3 weeks 
Weekly 
47 
7 
-0.621 0.400  0.1270  - - - 
Median Age 
≥63 
<63 
25 
22 
-0.201 0.250  0.4257  - - - 
% of male patients 
≥70 
<70 
25 
29 
0.441 0.259  0.0944  Excluded - - 
% of PS2 patients 
≥10 
<10 
21 
32 
0.004 0.287  0.9877  - - - 
% of patients with Stage IV disease 
≥80 
<80 
25 
28 
-0.498 0.253  0.0545  Excluded - - 
% of patients with Adenocarcinoma  
≥55 
<55 
23 
24 
-0.442 0.255  0.0890  Excluded - - 
PFS: progression free survival, TTP: time to progression, PS: Performance Status, SE: standard error, N: number of treatment arms,  
- : not used in the multiple regression analysis because p > 0.1, Excluded: excluded as a result of the step wise approach using p < 0.05 
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Table 4 Factors influencing ORR identified by logistic regression analysis (Carboplatin and paclitaxel as first line therapy) 
Characteristics Category N 
Univariate analysis Multivariate analysis 
OR 95%CI P value OR 95%CI P value 
Year of trial initiation 
2003-2008 
1995-2002 
21 
36 
0.984 0.905-1.070 0.7031 - - - 
Phase  
III  
II 
36 
25 
0.949 0.849-1.060 0.3547 - - - 
Trial Region 
Non -Asia  
Asia 
45 
11 
0.743 0.661-0.833 < 0.0001 0.580 0.508-0.662 < 0.0001 
No. of randomized patients 
≥160 
<160 
30 
31 
0.988 0.897-1.088 0.8046 - - - 
Administration schedule of Paclitaxel 
Every 3 weeks 
Weekly 
52 
9 
0.752 0.669-0.845 < 0.0001 0.815 0.716－0.929 0.0021 
Median Age 
≥63 
<63 
27 
26 
0.969 0.891-1.054 0.4631 - - - 
% of male patients 
≥70 
<70 
26 
35 
1.284 1.186-1.391 < 0.0001 Excluded - - 
% of PS 2 patients 
≥10 
<10 
23 
36 
1.170 1.075-1.273 0.0003 Excluded - - 
% of patients with Stage IV disease 
≥80 
<80 
30 
30 
0.832 0.769-0.900 < 0.0001 Excluded - - 
% of patients with Adenocarcinoma  
≥55 
<55 
25 
26 
0.792 0.729-0.861 < 0.0001 0.661 0.595－ 0.735 < 0.0001 
ORR: overall response rate, OR: odds ratio, PS: performance status, CI: confidential interval, N: number of treatment arms,  
- : not used in the multiple regression analysis because p > 0.1, Excluded: excluded as a result of the step wise approach using p < 0.05 
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3.2. Docetaxel as second-line therapy 
3.2.1. Trial Characteristics 
The flowchart for trial selection is shown (Figure 2). A total of 116 articles were retrieved. As a result of 
manual literature review, 31 trials were ultimately selected to establish the database for the meta-analysis 
[62-92]. 
 
Figure 2 Flowchart of selecting trials for the analysis 
ORR: overall response rate, OS : overall survival 
 
Main characteristics of the 31 trials are listed (Table 5). A total of 39 treatment arms and 5,312 patients with 
advanced NSCLC were included. The median number of patients per trial was 73(range 25–697) with most 
trials having a high proportion of males (75.0 %: range 57.0-93.0%). The median age was 60 years (range 
55.0-68.0). There were 19 arms from phase II and 20 arms from phase III trials. Classifications of trials by 
year of trial start were between 1998 and 2002 (20 arms) and between 2003 and 2010 (16 arms). The median 
OS was 7.4 months (range 4.7-22.9) for all arms, and median PFS/TTP was 2.8 months (range 1.4-4.8) for 37 
arms. The median overall response rate was 8.8 % for all arms (range 2.1-24.0). 
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Table 5 Characteristics of 39 treatment arms in the selected trials for the analysis 
Variables Overall 
Total number of trials 31 
Total number of arms 39 
Total number of patients 5,312 
Number of randomized patients per arm  
<75 20 
≥75 19 
Median (range) 73 (25-697) 
Phase a  
II 19 (48.7%) 
III 20 (51.3%) 
Year of trial initiation a  
1998-2002 20 (51.3%) 
2003-2010 16 (41.0%) 
Unknown 3 (7.7%) 
Trial Region a  
Asia 10 (25.6%) 
Non-Asia 24 (61.5%) 
Others 5 (12.9%) 
Treatment line of Docetaxel a  
Second line 30 (76.9%) 
≥Second/ line 9 (23.1%) 
Administration schedule of Docetaxel a  
Weekly 9 (23.1%) 
Every 3 weeks 27 (69.2%) 
Others 3(7.7%) 
Median Age(range) 60.0 (55.0-68.0) 
Percentage of male patients (range) 75.0 (57.0-93.0) 
Percentage of PS2 patients (range) 15.0 (0-74.0) 
Percentage of patients with Stage IV disease(range) 80.8 (48.0-100) 
Percentage of patients with Adenocarcinoma (range) 48.3 (26.0-75.0) 
ORR (%)(range)  8.8 (2.1-24.0) 
PFS/TTP (months) (range)  2.8 (1.4-4.8) 
OS (months) (range) 7.4 (4.7-22.9) 
ORR: overall response rate, PFS: progression free survival, TTP: time to progression, OS: overall survival, 
PS: performance status 
a number of treatment arms (%) 
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3.2.2. Regression analysis 
I selected year of trial initiation (1998–2002, 2003–2010), trial phase (II, III), trial region (Asia, 
non -Asia), number of patients (<75, ≥75), docetaxel administration schedule (weekly, every 3 
weeks), treatment line of docetaxel (second line, second or more line ), median age (<60, ≥60), 
percentage of male patients (<75, ≥75), percentage of PS2 patients (<15, ≥15), percentage of 
patients with stage IV disease (<80, ≥80), and percentage of patients with adenocarcinoma (<50, 
≥50) as potential influencing factors. 
Identification of factors influencing OS 
In simple and linear regression analyses to identify factors influencing OS, year of trial 
initiation, trial region, percentage of male patients, percentage of PS2 patients and percentage of 
patients with adenocarcinoma were identified as factors potentially contributing to OS 
prolongation. Upon further multiple linear regression analyses, trial region (Asia) and patients 
with PS 2 less than 15 % of enrolled patients were identified as favorable factors significantly 
contributing to longer OS (Table 6). 
Identification of factors influencing PFS/TTP 
Year of trial initiation, trial region, median age, percentage of male patients, percentage of PS 2 
patients, percentage of patients with stage IV disease and percentage of patients with 
adenocarcinoma were identified as factors potentially contributing to PFS or TTP prolongation 
in simple and linear regression analyses. Upon further multiple linear regression analyses, 
patients with PS 2 less than 15 % of enrolled patients was identified as favorable factors 
significantly contributing to longer PFS/TTP (Table 7). 
Identification of factors influencing ORR 
In univariate logistic regression analyses, trial region, treatment line of docetaxel, percentage of 
male patients and percentage of patients with stage IV disease were identified as factors 
potentially influencing ORR. Upon further multivariate logistic regression analyses, second or 
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more line treatment of docetaxel, male patients less than 75% and patients with stage IV less 
than 80% of enrolled patients were identified as favorable factors significantly influencing ORR 
(Table 8). 
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  Table 6 Factors influencing OS identified by linear regression analysis (Docetaxel as second line therapy) 
Characteristics Category N 
Simple linear regression Multiple linear regression 
Regression coefficient SE P value Regression coefficient SE P value 
Year of trial initiation 
2003-2010 
1998-2002 
16 
20 
2.461 0.592 0.0002 Excluded - - 
Phase  
III 
 II 
20 
19 
1.172 0.861 0.1818 - - - 
Trial Region 
Non –Asia 
 Asia 
24 
10 
-4.176 0.828 <0.0001 -3.598 0.902 0.0003 
No. of randomized patients 
≥75 
<75 
19 
20 
0.417 0.882 0.6391 - - - 
Treatment line of Docetaxel 
≥Second/ line 
Second line 
9 
30 
-0.428 0.945 0.6535 - - - 
Administration schedule of Docetaxel 
Every 3 weeks 
Weekly 
27 
9 
1.687 1.050 0.1172 - - - 
Median Age 
≥60 
<60 
20 
15 
-0.329 0.756 0.6659 - - - 
% of male patients 
≥75 
<75 
20 
19 
-2.062 0.632 0.0024 Excluded - - 
% of PS2 patients 
≥15 
<15 
19 
18 
-2.795 0.596 <0.0001 -2.725 0.850 0.0041 
% of patients with Stage IV disease 
≥80 
<80 
15 
14 
0.498 0.821 0.5495 - - - 
% of patients with Adenocarcinoma  
≥50 
<50 
14 
18 
2.554 0.695 0.0009 Excluded - - 
OS : overall survival, PS: performance status, SE: standard error, N: number of treatment arms,  
- : not used in the multiple regression analysis because p > 0.1, Excluded: excluded as a result of the step wise approach using p < 0.05 
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Table 7 Factors influencing PFS/TTP identified by linear regression analysis (Docetaxel as second line therapy) 
Characteristics Category N 
Simple linear regression Multiple linear regression 
Regression coefficient SE P value Regression coefficient SE P value 
Year of trial initiation 
2003-2010 
1998-2002 
16 
18 
0.409 0.238 0.0955 Excluded - - 
Phase  
III 
II 
18 
19 
0.311 0.299 0.3054 - - - 
Trial Region 
Non –Asia  
Asia 
22 
10 
-0.493 0.281 0.0892 Excluded - - 
No. of randomized patients 
≥75 
<75 
17 
20 
0.145 0.303 0.6354 - - - 
Treatment line of Docetaxel 
≥Second/ line 
Second line 
9 
28 
0.200 0.324 0.5400 - - - 
Administration schedule of Docetaxel 
Every 3 weeks 
Weekly 
26 
8 
-0.034 0.403 0.9328 - - - 
Median Age 
≥60 
<60 
18 
15 
-0.547 0.239 0.0292 Excluded - - 
% of male patients 
≥75 
<75 
18 
19 
-0.543 0.239 0.0297 Excluded - - 
% of PS2 patients 
≥15 
<15 
17 
18 
-0.640 0.244 0.0131 -1.163 0.375 0.0113 
% of patients with Stage IV disease 
≥80 
<80 
13 
14 
0.706 0.242 0.0074 Excluded - - 
% of patients with Adenocarcinoma  
≥50 
<50 
13 
17 
0.686 0.279 0.0205 Excluded - - 
PFS: progression free survival, TTP: time to progression, PS: Performance Status, SE: standard error, N: number of treatment arms,  
- : not used in the multiple regression analysis because p > 0.1, Excluded: excluded as a result of the step wise approach using p < 0.05 
30 
 
 Table 8 Factors influencing ORR identified by logistic regression analysis (Docetaxel as second line therapy) 
Characteristics  Category N 
Univariate analysis Multivariate analysis 
OR 95%CI P value OR 95%CI P value 
Year of trial initiation  
2003-2010 
1998-2002 
16 
20 
1.016 0.837-1.233 0.8760 - - - 
Phase  
III 
II 
20 
19 
0.859 0.680-1.085 0.2022 - - - 
Trial Region 
Non -Asia 
Asia 
24 
10 
0.753 0.568-0.999 0.0494 Excluded - - 
No. of randomized patients  
≥75 
<75 
19 
20 
0.885 0.700-1.119 0.3075 - - - 
Treatment line of Docetaxel  
≥Second/ line 
Second line 
9 
30 
1.262 0.990-1.610 0.0604 1.467 1.027-2.096 0.0353 
Administration schedule of Docetaxel  
Every 3 weeks 
Weekly 
27 
9 
1.142 0.847-1.539 0.3852 - - - 
Median Age  
≥60 
<60 
20 
15 
1.019 0.835-1.243 0.8562 - - - 
% of male patients  
≥75 
<75 
20 
19 
0.692 0.561-0.852 0.0005 0.435 0.305-0.620 <0.0001 
% of PS2 patients  
≥15 
<15 
19 
18 
0.932 0.759-1.143 0.4965 - - - 
% of patients with Stage IV disease  
≥80 
<80 
15 
14 
1.730 1.385-2.161 <0.0001 0.563 0.368-0.860 0.0079 
% of patients with Adenocarcinoma  
≥50 
<50 
14 
18 
1.015 0.803-1.284 0.8984 - - - 
ORR overall response rate, OR Odds ratio, PS: performance status, CI: confidential interval, N: number of treatment arm,  
- : not used in the multiple regression analysis because p > 0.1, Excluded: excluded as a result of the step wise approach using p < 0.05 
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3.3. The comparison of overall outcomes 
3.3.1. Outcomes between Asian and non-Asian trials 
Carboplatin and paclitaxel as first-line therapy 
In comparisons between Asian and non-Asian trials, significant differences in median OS (14.1 
and 9.0 months, P< 0.0001) and ORR (32.4% and 25.6%, P=0.004) were identified, while 
median PFS/TTP was found not to be significantly different (5.8 and 4.9 months, P=0.1339) 
(Table 9 and Figure 3,4 and 5). 
Table 9 Outcomes in Asian and non-Asian trials 
Median OS Median PFS/TTP Median ORR 
Asian 
trials 
Non- Asian 
trials 
P* Asian trials Non-Asian 
trials 
P* Asian trials Non-Asian 
trials 
P* 
14.1 (11) 9.0 (45) <0.0001 5.8 (11) 4.9 (38) 0.1339 32.4% (11) 25.6% (45)  0.004 
OS: overall survival, TTP: time to progression, PFS: progression-free survival, ORR: overall 
response rate, ( ) number of treatment arms 
P* Mann-Whitney U test 
 
 
Figure 3 Median overall survival in Asian and non-Asian trials 
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Figure 4 Median PFS/TTP in Asian and non-Asian trials 
 ( ) number of patients 
 
Figure 5 Overall response rate in Asian and non-Asian trials 
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Docetaxel as second-line therapy 
In comparisons between Asian and non-Asian trials, significant differences in median OS (9.8 
and 6.7 months, P＝0.0002) and PFS/TTP (3.2 and 2.7, P=0.0436) were identified, while 
median ORR was found not to be significantly different (11.5% and 8.3%, P=0.1733) (Table 10 
and Figure 6, 7 and 8). 
 
Table 10 Outcomes in Asian and non-Asian trials  
Median OS Median PFS/TTP Median ORR 
Asian 
trials 
Non- Asian 
trials 
P* Asian trials Non-Asian 
trials 
P* Asian trials Non-Asian 
trials 
P* 
9.8 (10) 6.7(24) 0.0002 3.2 (10) 2.7 (22) 0.0436 11.5% (10) 8.3% (24) 0.1733 
OS: overall survival, TTP: time to progression, PFS: progression-free survival, ORR: overall 
response rate, ( ) number of treatment arms 
P* Mann-Whitney U test 
 
 
Figure 6 Median overall survival in Asian and non-Asian trials 
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Figure 7 Median PFS/TTP in Asian and non-Asian trials 
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Figure 8 Overall response rate in Asian and non-Asian trials 
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3.3.2. Outcomes between trials treated with docetaxel as second line therapy in 
percentage of PS 2 patients 
In comparisons between trials treated with docetaxel as second line therapy in patient with PS 2 
of ≥15 and <15%, significant differences in median OS (9.2 and 6.7 months, P=0.0005) and 
PFS/TTP (3.1 and 2.6, P=0.031) were identified, while median ORR was found not to be 
significantly different (10.3% and 8.0%, P=0.3386) (Table 11 and Figure 9, 10 and 11). 
 
Table 11 Outcomes in trials in patient with PS 2 of ≥15 and <15% 
Median OS Median PFS/TTP Median ORR 
PS2 <15% PS2≥15 % P* PS2 <15% PS2≥15 % P* PS2 <15% PS2≥15 % P* 
9.2(18) 6.7(19) 0.0005 3.1 (18) 2.6 (17) 0.031 10.3% (18) 8.0% (19) 0.3386 
OS: overall survival, TTP: time to progression, PFS: progression-free survival, ORR: overall 
response rate, ( ) number of treatment arms 
P* Mann-Whitney U test 
 
 
Figure 9  Median overall survival in trials in patient with PS 2 of ≥15 and <15% 
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Figure 10  Median PFS/TTP in trials in patient with PS 2 of ≥15 and <15% 
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Figure 11  Overall response rate in trials in patient with PS 2 of ≥15 and <15% 
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4. Discussion 
4.1. Comparison of prognostic factors influencing OS, PFS, and ORR in each of the 
carboplatin/paclitaxel and docetaxel treatment groups 
4.1.1. Carboplatin and paclitaxel as first-line therapy 
When the result for ORR was compared with that for PFS, trial region (Asia), administration 
schedule of paclitaxel (weekly), and percentage of patients with adenocarcinoma (<55% of 
enrolled patients) were identified as factors contributing to higher ORR. However, none of these 
factors were identified as factors potentially influencing PFS. This suggests that none of the 
factors influencing ORR may contribute to PFS prolongation. Furthermore, when the result for 
PFS was compared with that for OS, no factors influencing PFS were identified, whereas trial 
region (Asia) was identified as a factor contributing to OS prolongation. Higher ORR did not 
appear to have any direct relation to OS prolongation in Asian trials. OS prolongation may be 
attributed to the treatment administered following treatment with carboplatin and paclitaxel as 
first-line chemotherapy in Asian trials.  
4.1.2. Docetaxel as second-line therapy 
When the result for ORR was compared with that for PFS, treatment line of docetaxel (second- 
or more line treatment), proportion of male patients (<75% of enrolled patients), and proportion 
of patients with Stage IV disease (<80% of enrolled patients) were identified as factors 
contributing to higher ORR. The proportion of patients with PS 2 (<15% of enrolled patients) 
was identified as a factor contributing to PFS prolongation. This suggests that none of the 
factors influencing ORR may contribute to PFS prolongation. When the result for PFS was 
compared with that for OS, the proportion of patients with PS 2 (<15% of enrolled patients) was 
identified as a factor contributing to PFS prolongation, whereas trial region (Asia) and 
proportion of patients with PS 2 (<15% of enrolled patients) were identified as factors 
contributing to OS prolongation. Good performance status may contribute to PFS prolongation 
that may be related to OS prolongation. Furthermore, trial region (Asia) was not identified as a 
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factor influencing PFS. Thus, as observed for carboplatin and paclitaxel as first-line 
chemotherapy, OS prolongation may be attributed to the treatment administered following 
treatment with docetaxel as second-line chemotherapy in Asian trials. 
 
4.2. Comparison of prognostic factors affecting OS, PFS, and ORR between 
carboplatin/paclitaxel and docetaxel treatment groups 
When prognostic factors influencing OS, PFS, and ORR were compared between 
carboplatin/paclitaxel and docetaxel treatment groups, the trial region (Asia) was identified as a 
common factor contributing to OS prolongation. In general, either administration of TK 
inhibitors, chemotherapy (for patients ineligible for treatment with TK inhibitors), or supportive 
care is available for subsequent treatment following treatment with carboplatin/paclitaxel as 
first-line chemotherapy and docetaxel as second-line chemotherapy. It has been reported that 
EGFR mutation is a prognostic factor for a favorable outcome of patients with NSCLC treated 
with TKIs, such as gefitinib and elrotinib [93-98], and such mutations are more frequently 
observed in East-Asians compared with Americans and non-East Asians [99-102]. Treatment 
with TKIs as a subsequent therapy may play a role in the OS benefit observed in Asian regions. 
Also, one of the common factors in these treatment options, management of subsequent 
treatment, may differ between Asian and non-Asian regions. Subsequent treatment options may 
be selected according to either established treatment guidelines or daily medical practice within 
affordable range of patient financial burden for medical care. More specifically, differences in 
the health insurance system in each country may lead to differences in the management of 
subsequent treatment because a cost of molecular targeted drugs such as TKIs and genetic test 
before TKIs treatment is typically high all over the word. Health insurance systems differ 
depending on the country in terms of organization (public or private), coverage area, patient 
charge, and so on. These differences may correlate with the opportunity of accessing subsequent 
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treatments. Furthermore, it is assumed that the ability to access specialized hospitals during 
cancer treatment differs among each country [103-104]. Patients can receive well-supported 
treatment in line with the established treatment guideline at specialized hospitals because there 
is enough expertized medical staff and a leading-edge diagnostic test such as a screening of 
EGFR mutation is implemented. On the other hand, patients receive affordable treatment 
without choices at non-specialized hospitals according to daily medical practice. These 
differences may correlate with those of OS. Therefore, it is important to collect data on 
subsequent treatment in clinical trials to support these points. 
In the docetaxel group, the proportion of patients with PS 2 (<15% of enrolled patients) was 
identified as a factor contributing to both PFS and OS prolongation, whereas in the 
carboplatin/paclitaxel treatment groups, the proportion of patients with PS 2 was not identified 
as a factor influencing PFS nor OS. On the basis of this result, PFS prolongation may be 
attributed to good PS during treatment with docetaxel as second-line chemotherapy, and PFS 
prolongation may continuously contribute to OS prolongation. 
 
4.3. Points to consider for clinical trials assessing efficacy of novel agents combined with 
standard chemotherapy for NSCLC treatment  
Our analysis demonstrated that in clinical trials on patients with NSCLC treated with 
carboplatin/paclitaxel and docetaxel, patients in Asian trials had a better OS than those in 
non-Asian trials. OS prolongation may be attributed to the subsequent treatment in Asian trials 
that suggests that the overall OS measurement of novel agents combined with 
carboplatin/paclitaxel and docetaxel can be skewed by the effect of subsequent therapies in 
Asian regions. However, it is clinically meaningful to measure OS as a primary endpoint in 
global clinical trials on patients with NSCLC because OS directly provides universal evidence 
of clinical benefit of the agent across regions. 
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OS is a gold standard endpoint for confirmatory phase III clinical trials assessing the efficacy of 
novel agents for the treatment of NSCLC because the true clinical benefit of therapeutic agents 
can be evaluated through this measure [105]. Using OS as a primary endpoint, more large-scale 
studies, including >1,000 patients, are expected to be conducted. Large-scale clinical trials have 
to rely on multinational trials, and it is difficult to repeatedly conduct similar trials. Therefore, it 
is very important to prepare proactive measures towards bringing the clinical trial to a 
successful result. In the present study, trial region (Asia) and low proportion of patients with PS 
2 were identified as prognostic factors contributing to OS prolongation. When designing global 
phase III trials, this information is critical to assessing the efficacy of novel therapeutic agents in 
combination with carboplatin/paclitaxel or docetaxel. Adjustment without excessive bias of the 
ratio of the number of patients per region and addition of race and region as stratification factors 
should be considered. Furthermore, the ratio of the number of patients with PS 2 should be 
adjusted within the range of general medical practice in clinical trials of novel agents combined 
with docetaxel as second-line chemotherapy. 
In diseases with a relatively long OS, such as NSCLC, OS may be strongly affected by the 
subsequent treatment; hence, OS prolongation may be attributed to the subsequent treatment 
after disease progression. Owing to this factor, treatment response to subsequent therapies is 
suggested to differ among countries. Thus, information regarding the subsequent treatment 
should be collected in clinical trials to completely understand its influence on OS. 
 
4.4. Limitation 
The present meta-analysis has a few limitations. First, we conducted the analysis on the basis of 
limited data that were available through publications of clinical trial results and not on 
individual patient data. In general, meta-analyses on the basis of individual patient data can be 
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used to more carefully investigate the influence of covariates on the heterogeneity of treatment 
effect both within and between trials and would provide robust estimates [106]. Second, data on 
the rate of EGFR mutation and subsequent treatment after disease progression were not included 
in our meta-analysis because of the limited data availability; such data may be important to 
develop a better understanding of prognostic factors influencing OS. 
 
5. Conclusion 
In conclusion, the region of Asia was identified as a prognostic factor of prolonged OS in 
treatment with carboplatin and paclitaxel as first-line chemotherapy and docetaxel as 
second-line chemotherapy. In addition, we identified a low proportion of patients with PS 2 as a 
factor contributing to longer OS in treatment with docetaxel as second-line chemotherapy. The 
findings of the present study reflect actual medical practice and circumstances with various 
patient backgrounds irrespective of the subsequent treatments in line with either established 
guidelines or daily medical practice in each county, which are expected to continue. More global 
clinical trials on NSCLC are expected to be conducted across regions and our finding, i.e., 
regional differences between Asian and non-Asian population, including Caucasians, should be 
considered in study design and interpretation of results of global clinical trials. Furthermore, the 
ratio of patients with PS 2 should be considered in the design of global clinical trials of novel 
agents used in combination with docetaxel as second-line chemotherapy. 
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8. Supplementary data 
Table 12 Detailed data of selected trials (Carboplatin and paclitaxel as first line therapy) 
Trial Reference 
Year of 
trial 
initiation 
phase Trial region 
Administration 
schedule of 
paclitaxel 
No of pts 
(CP arm) 
Age  Male pts 
PS2  
pts 
Pts with 
Adeno  
pts with 
stage IV 
ORR PFS/TTP  OS  
Scagliotti GV et 
al, 2012 
[9] 2007 III Others Every 3 weeks 549 60 61% NA 81% 86% 26% 5.4 11 
Lilenbaum R, et 
al, 2008 
[10] 2002 II Non-Asia  Every 3 weeks 51   NA 55.0% 100.0% 62.7% 86% 12% 3.5 9.5 
Lynch TJ et al 
2012 
[11] 2008 II Non-Asia Every 3 weeks 66 62 74% 0.0% 58% 74% 14% 4.21 8.28 
Niho S et al, 
2012 
[12] 2007 II Asia Every 3 weeks 59 60 64% 0.0% 93% 71% 31% 5.9 23.4 
Soria JC et 
al,2011 
[13] 2007 II Non-Asia Every 3 weeks 41 62 59% 0.0% 37% 98% 39% 6.1 10.1 
Quoix E et al [14] 2006 III Non-Asia Weekly 225 77.4 71.6% 27.1% 50.7% 80% 27.1% 6 10.3 
Lara PN Jr et al 
2011 
[15] 2008 III Others Every 3 weeks 650 61 62.3% 0.0% 67.1% 90.9% 24.6% 5.5 12.7 
Hirsh V et al [16] 2005 III Others Every 3 weeks 420 62 65% 0.7% 58% 88% 23% 4.7 9.8 
Digumarti R et 
al 2011 
[17] 2004 II Non-Asia Every 3 weeks 55 56.1 84% 0.0%   NA 62% 27% 4.2 8.5 
Han B et al 2011 [18] 2007 II Asia Every 3 weeks 61 58 62.3% 3.3% 67.2% 59% 23% 6.3 15.8 
Saito H at al 
2012 
[19] 2001 II Asia Every 3 weeks 41 65 73.2% 100.0% 65.9% 82.9% 29.3% 2.9 5.9 
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Trial Reference 
Year of 
trial 
initiation 
phase Trial region 
Administration 
schedule of 
paclitaxel 
No of pts 
(CP arm) 
Age  Male pts 
PS2  
pts 
Pts with 
Adeno  
pts with 
stage IV 
ORR PFS/TTP  OS  
Biesma B et al 
2011 
[20] 2003 III Non-Asia Every 3 weeks 91 74 76% 15.0% 30% 69% 19% 4.5 6.9 
Weissman CH et 
al 2011 
[21] 2004 III Non-Asia Every 3 weeks 192 64 56.3% 0.0% 55.2% 84.4% 22.4% 4.67 9.24 
Okamoto I et al 
2010 
[22] 2006 III Asia Every 3 weeks 281 63 76.5% 0.0% 69.4% 75.8% 29% 4.8 13.3 
Belani CP et all 
2008 
[23] 2000 III Non-Asia Weekly 223 65 60% 12.0% 57% 82% 27.6% 4.23 8.88 
Belani CP et all 
2008 
[23] 2000 III Non-Asia Every 3 weeks 221 65 65% 10.0% 58% 83% 19.2% 3.84 9.87 
Goss GD 2010 [24] 2005 II Non-Asia Every 3 weeks 125 58 59% 0.0% 48%   NA 16% 5 10.1 
Blumenschein 
GR et al 2008 
[25] 2002 III Non-Asia Every 3 weeks 306 63 66% 0.0% 50% 87% 23.5% 4.9 9.2 
Scagliotti G, et 
al 2010 
[26] 2006 III Others Every 3 weeks 462 63.0  62% 0.0% 59% 90% 24.0% 5.4 10.6 
Herbst RS et 
all 2005 
[27] 2001 III Non-Asia Every 3 weeks 539 63 61.6% 0.2% 61.4% 82.2% 19.3% 4.9 10.5 
Herbst RS et al 
2004 
[28] 2000 III Non-Asia Every 3 weeks 345 63 61.4% 9.3% 51.9% 78.3% 28.7% 5.0  9.9 
Leighl NB et al 
2005 
[29] 2000 III Non-Asia Every 3 weeks 387 61.4 73% 11.0% 52% 79% 33.7% 5.3 9.2 
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Trial Reference 
Year of 
trial 
initiation 
phase Trial region 
Administration 
schedule of 
paclitaxel 
No of pts 
(CP arm) 
Age  Male pts 
PS2  
pts 
Pts with 
Adeno  
pts with 
stage IV 
ORR PFS/TTP  OS  
Lilenbaum RC 
et al 2005 
[30] 1997 III Non-Asia Every 3 weeks 284 64 68% 17.0% 51% 87% 30%   NA 8.8 
Heymach JV et 
al 2008 
[31] 2004 II Non-Asia Every 3 weeks 52 59 71% 0.0% 50% 90% 25% 5.3 12.6 
Langer C et al 
2007 
[32] 2000 II Non-Asia Every 3 weeks 51 65 74% 100.0% 51% 79% 14% 3.5  6.2 
Paccagnella A et 
al 2006 
[33] 1998 III Non-Asia Every 3 weeks 159 61 82% 6.0% 43% 64% 20% 5.1 8.3 
Williamson SK 
et al 2005 
[34] 2000 III Non-Asia Every 3 weeks 186 62.6 63% 0.0%   NA 87% 35% 5 9 
Ohe Y et al 2007 [35] 2000 III Asia Every 3 weeks 145 63 68.3% 0.0% 72% 81% 32.4% 4.5 12.3 
Kubota K, et al 
2008 
[36] 2001 III Asia Every 3 weeks 197 65 69% 0.0% 76% 83% 37.1% 5.8 14.1 
Sakakibara T et 
al 2010 
[37] 2004 II Asia Weekly 42 74 90% 0.0% 52% 60% 55% 6.0  14.7 
Sakakibara T et 
al 2010 
[37] 2004 II Asia Every 3 weeks 40 75 77.5% 0.0% 42.5% 55% 53% 5.6 15.5 
Stathopoulos GP 
et al 2004 
[38] 2000 III Non-Asia Every 3 weeks 185 65 86.5% 20.0% 44.3% 49.2% 46.0% 7 11 
Scagliotti GV 
etal 2002, 
[39] 1998 III Non-Asia Every 3 weeks 201 62 76% 8.0% 48% 82% 32% 5.5 10 
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Trial Reference 
Year of 
trial 
initiation 
phase Trial region 
Administration 
schedule of 
paclitaxel 
No of pts 
(CP arm) 
Age  Male pts 
PS2  
pts 
Pts with 
Adeno  
pts with 
stage IV 
ORR PFS/TTP  OS  
Schiller JH, et 
al2002 
[40] 1996 III Non-Asia Every 3 weeks 299 63 62% 5.0%   NA 86% 17% 3.1 8.1 
Rosell R, et al 
2002 
[41] 1996 III Non-Asia Every 3 weeks 309 58 83% 17.0% 47% 62% 25% 3 8.5 
Sandler A et al 
2006 
[42] 2001 III Non-Asia Every 3 weeks 433   NA 58% 0.0% 88% 78% 15.1% 4.5 10.3 
Belani CP et al 
2005 
[43] 1995 III Non-Asia Every 3 weeks 190   NA 66% 0.0%   NA 77% 23% 3.98 7.66 
Kosmidis P, et al 
2002 
[44] 1998 III Non-Asia Every 3 weeks 238 63 87.0% 14.0% 47.0% 62.0% 28% 6.3 10.4 
Kelly K et al 
2001 
[45] 1996 III Non-Asia Every 3 weeks 206 62 70% 0.0%   NA 88% 25% 4 8.6 
Treat JA et al [46] 2000 III Non-Asia Every 3 weeks 379 64.1 60.9% 0.3% 83.9% 89.4% 29.8% 4.7 8.7 
Mok TS et al [47] 2006 III Asia Every 3 weeks 608 57 20.9% 10.7% 97.2% 76.2% 32.2% 5.8 17.3 
Langer CJ et 
al 2008 
[48] 2002 III Non-Asia Every 3 weeks 201 63 78% 100.0%   NA 73% 37% 4.56 7.85 
Pathak AK et al 
2005 
[49] 1998 II Non-Asia Every 3 weeks 72 54 83.6%  NA 26.2% 39.7% 33%   NA 9 
Lilenbaum RC 
et al 2005 
[50] 2000 II Non-Asia Every 3 weeks 83 63 51% 16.0%   NA 81% 16.9% 4.8 8.6 
Chen YM et al 
2006 
[51] 2000 II Asia Every 3 weeks 40   NA 100% 47.5% 40% 82.5% 40% 6.6 10.3 
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Trial Reference 
Year of 
trial 
initiation 
phase Trial region 
Administration 
schedule of 
paclitaxel 
No of pts 
(CP arm) 
Age  Male pts 
PS2  
pts 
Pts with 
Adeno  
pts with 
stage IV 
ORR PFS/TTP  OS  
Chen YM et al 
2002 
[52] 1999 II Asia Every 3 weeks 45  NA  77.7% 35.6% 48.9% 62.2% 40% 5.7 14.1 
Marsland TA et 
al2005 
[53] 1999 II Non-Asia Weekly 60  NA  60% 28.3%  NA  70.5% 60.9%   NA 9.2 
Belani CP ,et al 
2003 
[54] 1998 II Non-Asia Weekly 132 65 59% 14.0% 56% 77.0% 32% 6.9 11.3 
Belani CP ,et al 
2003 
[54] 1998 II Non-Asia Weekly 130 63 65% 14.0% 47% 77.0% 24% 4.8 7.1 
Belani CP ,et al 
2003 
[54] 1998 II Non-Asia Weekly 128 64 61% 15.0% 58% 78.0% 18% 6.2 9.2 
Socinski MA, et 
al 2006 
[55]  NA  II Non-Asia Every 3 weeks 81 61 67.0% 0.0%   NA 88% 32%   NA 6.6 
Socinski MA, et 
al 2006 
[55]  NA  II Non-Asia Weekly 80 60 62.0% 0.0%   NA 88% 36%   NA 8.7 
Kosmidis P et al 
2000 
[56] 1996 II Non-Asia Every 3 weeks 99 62.4 89% 15.0% 38.4% 71% 25.6% 4.3 9.5 
Kosmidis P et al 
2000 
[56] 1996 II Non-Asia Every 3 weeks 99 59.4 85% 10.0% 38.4% 69% 31.8% 6.4 11.4 
Socinski MA,et 
al 2002 
[57] 1998 III Non-Asia Every 3 weeks 114 62 63% 0.0% 78% 88% 22%   NA 6.6 
Socinski MA,et 
al 2002 
[57] 1998 III Non-Asia Every 3 weeks 116 66 62% 0.0% 78% 86% 24%   NA 8.5 
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Trial Reference 
Year of 
trial 
initiation 
phase Trial region 
Administration 
schedule of 
paclitaxel 
No of pts 
(CP arm) 
Age  Male pts 
PS2  
pts 
Pts with 
Adeno  
pts with 
stage IV 
ORR PFS/TTP  OS  
Schuette W et al 
2006 
[58]   NA III Non-Asia Weekly 457  NA  81% 6.0% 39% 69% 38% 6.1 8.9 
Schuette W et al 
2006 
[58]   NA III Non-Asia Every 3 weeks 464   NA 83% 7.0% 41% 72% 33% 7.2 9.5 
Laurie SA et al [59] 2008 III Non-Asia Every 3 weeks 153 62 54% 0.0% 65% 95% 34% 5.5 12.1 
Paz-Ares L et al 
2013 
[60] 2008 II Non-Asia Every 3 weeks 59 62 69% 0.0% 56% 90% 25% 5.5 7.8 
Socinski MA et 
al 2012 
[61] 2007 III Others Every 3 weeks 531 60 75% 0.03% 50% 79% 25% 5.8 11.2 
Adeno: Adenocarcinoma, CP: Carboplatin and paclitaxel, NA: Not available, pts: patients, ORR: overall response rate, OS: overall survival, PFS: progression-free survival, PS: performance 
status 
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Table 13  Detailed data of selected trials (Docetaxel as second line therapy) 
Trial Reference 
Year of 
trial 
initiation 
phas
e 
treatment 
line of 
docetaxel 
Trial 
region 
Administrati
on schedule 
of docetaxel 
No of pts 
(Doc arm) 
Age male pts 
PS2 
pts 
Pts with 
Adeno 
Pts with 
Stage IV 
ORR 
PFS/TT
P 
OS 
Garon EB et al 
2014 
[62] 2010 III 2 Others 
Every 3 
weeks 
625 61 66.0% 0.0%  NA 100% 14% 3.0 9.1 
Kawaguchi T et 
al 2014 
[63] 2009 III 2,3 Asia 
Every 3 
weeks 
151 67 70.9% 4.0% 68.2% 80.8% 17.9% 3.2 12.2 
Reck M et al 
2014 
[64] 2008 III 2 Others 
Every 3 
weeks 
659 60 72.7% 0.0% 51.0% 61.9% 3.3% 2.7 9.1 
Garassino MC  
et al 2013 
[65] 2007 III 2 Non-Asia Others 110 67 66.0% 6.0% 75.0%  NA 15.5% 2.9 8.2 
Sun Y et al 2013 [66] 2006 III 2 Asia 
Every 3 
weeks 
104 55.8 58.7% 10.6% 70.2% 80.8% 4.1% 3.1 12.2 
Manegold C et 
al 2013 
[67] 1999 II 2 Non-Asia 
Every 3 
weeks 
34  NA 65.0% 21.0% 26.0% 91.0% 15.0% 2.2 6.4 
Belvedere O et 
al 2011 
[68] 2005 II 2 Non-Asia 
Every 3 
weeks 
25 60 80.0% 0.0% 36.0% 92.0% 8.0% 1.7 7.1 
Ready N et al 
2011 
[69] 2007 II 2 Non-Asia 
Every 3 
weeks 
52 59.5 75.0% 14.0% 27% 48.0% 2.1% 1.6 5.9 
Vergnenegre A 
et al 2011 
[70] 2006 III 2 Non-Asia 
Every 3 
weeks 
75 59.4 85.3%  NA  NA 78.7% 10.7% 2.8 8 
Pallis AG et al 
2010 
[71] 2004 III 2 Non-Asia Others 65 63.0 86.2% 18.5% 47.7% NA  7.7% 2.6 7.7 
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Segawa Y et al 
2010 
[72] 2005 II 2 Asia 
Every 3 
weeks 
29 63.0 79.3% 0.0% 72.4% 79.3% 20.7% 3.7 22.9 
Herbst RS et al 
2010 
[73] 2006 III 2 Others 
Every 3 
weeks 
697 59.0 68.0% 0.3% 60.0% 85.0% 10.0% 4.2 9.9 
Krzakowski M 
et al 2010 
[74] 2003 III 2 Others 
Every 3 
weeks 
277 60.0 75.3%  NA 43.6% 61.8% 5.5% 2.3 7.2 
Lee DH et al 
2010 
[75] 2005 III 2 Asia 
Every 3 
weeks 
79 58.0 57.0% 6.3% 69.6%  NA 7.6% 3.4 12.2 
Takeda K et al 
2009 
[76] 2002 III 2 Asia 
Every 3 
weeks 
65 62.0 73.8% 0.0% 61.5%  NA 6.8% 2.1 10.1 
Gebbia V et al 
2009 
[77] 2005 III 2 Non-Asia Weekly 47 62.0 77.0% 2.0% 45.0% 89.0% 6.4% 2.9 9.2 
Jones S et al 
2008 
[78] 2000 II 2 Non-Asia 
Every 3 
weeks 
38 61.5 60.5% 15.8%  NA NA  8.0% 1.4 7.6 
Paz-Ares L et al 
2008 
[79] 2002 III 2 Non-Asia 
Every 3 
weeks 
422 63.0 71.6% 15.0%  NA 81.0% 12.0% 2.6 6.9 
Heymach JV et 
al 2007 
[80] 2003 II 2 Non-Asia 
Every 3 
weeks 
41 58.0  66.0% 0.0% 48.8% 68.3% 12.0% 2.8 13.4 
Chen YM  et al 
2006 
[81] 2002 II 2,3 Asia Weekly 64  NA 69.0% 59.4% 60.9% 90.6% 17.2% 4.2 8.4 
Chen YM  et al 
2006 
[81] 2002 II 2,3 Asia Weekly 64 NA  66.0% 56.2% 65.6% 92.2% 10.9% 3.5  7.2 
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Chen YM  et al 
2006 
[81] 2002 II 2,3 Asia 
Every 3 
weeks 
33  NA 70.0% 60.6% 54.5% 90.9% 6.1% 2.8 9.5 
Cufer T et al 
2006 
[82] 2003 II 2 Non-Asia 
Every 3 
weeks 
73 59.5 70.0% 28.8% NA  NA  13.7% 3.4 7.1 
Camps C et al 
2006 
[83] 2000 III 2>= Non-Asia 
Every 3 
weeks 
129 61 93.0% 16.3% NA  82.9% 9.3% 2.7 6.6 
Camps C et al 
2006 
[83] 2000 III 2>= Non-Asia Weekly 125 62 92.0% 16.0% NA  84.8% 4.8% 2.9 5.4 
Lai CL et al 
2005 
[84]  NA II 2 Asia 
Every 3 
weeks 
25 68 76.0% 24.0% 40.0% 68.0% 12.0% 2.6 7.8 
Lai CL et al 
2005 
[84]  NA II 2 Asia Weekly 25 68 64.0% 28.0% 60.0% 76.0% 24.0% 3.0 7.3 
Schuette W et al 
2005 
[85] 2000 III 2>= Non-Asia 
Every 3 
weeks 
103 63 73.8% 11.7% 30.1% NA  12.6% 3.4 6.3 
Schuette W et al 
2005 
[85] 2000 III 2>= Non-Asia Weekly 105 63 73.3% 10.5% 44.8% NA  10.5% 3.3 9.2 
Pectasides D et 
al 2005 
[86] NA  II 2 Non-Asia 
Every 3 
weeks 
65 59 89.0% 12.0% 43.0% NA  14.0% 4.8 6.4 
Gervais R et al 
2005 
[87] 2000 II 2 Non-Asia 
Every 3 
weeks 
62 59 80.0% 21.0% 44.0% 66.0% 4.8% 2.1 5.8 
Gervais R et al [87] 2000 II 2 Non-Asia Weekly 63 58 81.0% 21.0% 37.0% 67.0% 3.2% 1.8 5.5 
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2005 
Wachters FM et 
al 2005 
[88] 2000 II 2 Non-Asia 
Every 3 
weeks 
56 59 79.0% 13.0% 45.0% 75.0% 16.0% 4.2 7.4 
Gridelli C et al 
2004 
[89] 2000 III 2 Non-Asia 
Every 3 
weeks 
110 62 80.0% 15.0% 53.0% 81.0% 2.7%  NA 6.7 
Gridelli C et al 
2004 
[89] 2000 III 2 Non-Asia Weekly 110 63 86.0% 16.0% 45.0% 91.0% 5.5%  NA 5.8 
Hanna N et al 
2004 
[90] 2001 III 2 Others 
Every 3 
weeks 
288 57 75.3% 12.4% 49.3% 74.7% 8.8% 2.9 7.9 
Quoix E et al 
2004 
[91] 1998 II 2 Non-Asia 
Every 3 
weeks 
93 59 82.8% 25.8% 46.2% 62.4% 8.6% 1.5 4.7 
Quoix E et al 
2004 
[91] 1998 II 2 Non-Asia Others 89 59.2 82.0% 22.5% 34.8% 51.7% 7.6% 2.1 6.7 
Esteban E et al 
2004 
[92] 1999 II 2,3 Non-Asia Weekly 35 55 82.9% 74.0% 51.0% NA  3.0% 2.4 6.0 
Adeno: Adenocarcinoma, CP: Carboplatin and paclitaxel, pts: patients, NA: Not available, ORR: overall response rate, OS: overall survival, PFS: progression-free survival, PS: performance 
status 
